GlassScriptPhysician profile
Elizabeth A Templeman
NPI 1164735189
$14,214.51
in general payments reported to CMS, 2019-2025
30 companies · $3,024 in 2025
The $3,024 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,001 · 2022: $2,964 · 2023: $3,739 · 2024: $3,487 · 2025: $3,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,092.18 |
| Education | $157.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,079.53 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,984.16 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,109.87 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $964.31 | 2021-2025 | Azstarys |
| Alkermes, INC. | $959.23 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Janssen Pharmaceuticals, INC | $863.40 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $802.79 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $795.07 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $575.20 | 2021-2025 | Rexulti |
| Noven Therapeutics, LLC | $574.99 | 2023-2025 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $564.87 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $498.30 | 2021-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $458.71 | 2021-2025 | Trintellix |
| Bausch Health US, LLC | $374.08 | 2022-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $363.87 | 2022-2024 | Jornay Pm |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $312.75 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $185.33 | 2021-2022 | |
| Tris Pharma INC | $138.42 | 2022-2025 | Dyanavel Xr |
| Noven Pharmaceuticals, INC. | $110.66 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $104.21 | 2025 | Jornay Pm |
| Biogen, INC. | $99.19 | 2024 | Zurzuvae |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $70.02 | 2025 | |
| Almatica Pharma LLC | $45.36 | 2025 | Loreev Xr |
| Neos Therapeutics, LP | $43.37 | 2023-2025 | Adzenys Xr-Odt |
| Sage Therapeutics, LLC | $39.36 | 2025 | Zurzuvae |
| Jazz Pharmaceuticals INC. | $22.86 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $22.41 | 2024 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $17.71 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $17.35 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $17.13 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Templeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.